Nearly One Million People Have Taken An Experimental

Nearly one million people have taken an experimental [/news/coronavirus/index.html coronavirus] vaccine developed by a Chinese state-run pharmaceutical company through the country's emergency-use programme, the firm has revealed.
[/news/china/index.html China] National Pharmaceutical Group (Sinopharm) also claimed to have received no reports of any 'serious adverse reactions' from those who had received the vaccine in emergency use.
The news comes as COVID-19 vaccines from American firms [/news/pfizer/index.html Pfizer] and Moderna are expected to be ready for US authorisation and distribution within weeks, setting the stage for Lạc Sơn Đại Phật inoculation to begin this year.
Sinopharm's Chairman Liu Jingzhen said nearly one million people had taken an experimental coronavirus vaccine it was developing for kynghidongduong.vn emergency use.

The picture shows an anti-COVID-19 dose being displayed at the booth of Sinopharm at a trade fair in Beijing on September 5
RELATED ARTICLES [# Previous] [# 1] [# Next] [/news/article-8735759/Oxford-coronavirus-vaccine-safe-triggers-robust-immune-response-phase-2-study-finds.html Don't bank on Oxford's Covid vaccine before Christmas:...] [/news/article-8936191/Government-considers-changing-anti-Covid-tier-December-2.html Boris Johnson warns Pfizer jab 'WON'T deliver knock-out...] [/news/article-8929299/Joe-Biden-announces-COVID-task-force-led-Obamas-surgeon-general-Vivek-Murthy.html Joe Biden starts appointment blitz with 5am announcement of...] [/news/article-8888105/Europe-coronavirus-Protests-continent-considers-second-lockdown.html Germany announces new four-week 'lockdown lite' that will...]



Share this article
Share


The news also comes as a new study has confirmed that Oxford University's COVID-19 jab is 'safe and provokes a robust immune response' in people of all ages.
China launched the emergency-use programme in July, which so far includes three vaccine candidates for essential workers and other limited groups of people even as clinical studies have yet to be completed to prove their safety and efficacy.
The latest revelations came from Sinopharm's Chairman Liu Jingzhen during an interview on Monday with [ ], an outlet affiliated to state-controlled media organisation Sichuan Daily Press Group.
The article was re-published by Sinopharm through its official account on [ ]